GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
Coingestion of Anticholinergics or Opioid Acetaminophenopioid combination products have been implicated in chronic overuse, likely due to an increasing opioid requirement leading to concomitantly increasing acetaminophen exposure
A licensed healthcare provider will review your health and medical history to determine if you qualify for GLP-1 treatment and discuss your options with you before prescribing medication
by Siouxie Boshoff on Apr 02, 2025 Glad you asked
Why choose QuickDrip IV Hydration for B12 IM injections
Diabetes 42 , 658661
